Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP
Authors:
- 19 May 2015
- journal article
- research article
- Published by Taylor & Francis in Biomarkers
- Vol. 20 (4) , 253-257
Abstract
Objective: To investigate the expression and prognostic value of miR-224 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent R-CHOP. Materials and methods: RT-PCR was used to determine the relative expression of miR-224, in 258 DLBCL patients and 40 normal lymphoid tissue specimens. Results: MiR-224 expression in DLBCL patients was significantly down-regulated compared to that in negative controls (p < 0.05). The 5-year progression-free survival and overall survival rates were significantly higher in the high-expression level group compared to the low-expression level group (p < 0.05). Conclusions: MiR-224 expression level is implicated as a prognostic marker for DLBCL patients treated with R-CHOP.Keywords
This publication has 20 references indexed in Scilit:
- Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOPJournal of Clinical Oncology, 2013
- CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapyAnnals of Hematology, 2012
- A microRNA signature differentiates between giant cell tumor derived neoplastic stromal cells and mesenchymal stem cellsCancer Letters, 2012
- Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphomaAnnals of Hematology, 2011
- Hsa‐miR‐375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarityThe Journal of Pathology, 2011
- MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOPClinical Cancer Research, 2011
- MicroRNA Expression Signatures of Bladder Cancer Revealed by Deep SequencingPLOS ONE, 2011
- Targeting microRNAs in cancer: rationale, strategies and challengesNature Reviews Drug Discovery, 2010
- Non-coding RNAs: a key to future personalized molecular therapy?Genome Medicine, 2010
- MicroRNAs in CancerAnnual Review of Medicine, 2009